GPSM2 and malignant colon neoplasm: Moreover, GPSM2 overexpression was linked to OS (p = 0.02), PPS (p = 0.0002), and relapse-free survival (RFS) (p = 1.8 × 10−6) in colon cancer patients (Figure 5B).